TNF and myeloid sarcoma: MS patients with a TNF receptor 1 (TNFR1) polymorphism, rs1800693, may be at particular risk of an adverse response to anti-TNF treatment because this SNP results in a soluble TNFR1 isoform that naturally antagonizes the action of TNF [89].